MINNETONKA, Minn.--(BUSINESS WIRE)--A.forall’s U.S. subsidiary Milla Pharmaceuticals Inc. announced the launch of the group’s generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 200 ...
ANDERLECHT, Belgium--(BUSINESS WIRE)--#FocusToGrow--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US ...
A.forall, which is backed by The Riverside Company, has acquired Provepharm’s US generics portfolio. No financial terms were disclosed. The deal includes four FDA-approved and marketed sterile ...
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results